# Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

> **NCT04539301** · — · RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 2100 (estimated)

## Conditions studied

- Anticoagulation
- Venous Thromboembolism
- Atrial Fibrillation

## Interventions

- **DIAGNOSTIC_TEST:** Estimated anticoagulant level (conversion factor x anti-Xa activity)

## Key facts

- **NCT ID:** NCT04539301
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 2100 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539301, "Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04539301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*